Related Experiment Video
Updated: Jul 13, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Phenformin and hyperamylasemia in lactic acidosis
Annals of Internal Medicine
|September 1, 1977
Summary
Hyperamylasemia, or elevated serum amylase, occurred in 67% of lactic acidosis patients. This finding was not linked to phenformin use, acidosis severity, or kidney function.
Area of Science:
- Biochemistry
- Clinical Medicine
- Pharmacology
Background:
- Lactic acidosis is a serious metabolic disturbance.
- Hyperamylasemia is a known complication in some critical illnesses.
- Phenformin, a medication, has been associated with lactic acidosis.
Purpose of the Study:
- To determine the frequency of hyperamylasemia in patients with lactic acidosis.
- To investigate the association between phenformin use and hyperamylasemia in lactic acidosis.
- To explore correlations between hyperamylasemia, acidosis severity, and renal function.
Main Methods:
- Retrospective review of lactic acidosis cases over 23 months.
- Analysis of serum amylase activity measurements in patients.
- Comparison of hyperamylasemia frequency between phenformin and non-phenformin groups.
- Correlation analysis with arterial pH and serum creatinine.
Main Results:
- Serum amylase was measured in 12 of 26 lactic acidosis patients.
- Hyperamylasemia was observed in 8 patients (67%).
- No significant difference in hyperamylasemia frequency was found between phenformin-associated and non-phenformin-associated lactic acidosis.
- Serum amylase levels did not correlate with acidosis severity or renal function.
Conclusions:
- Hyperamylasemia is common in patients with lactic acidosis.
- Phenformin use does not appear to increase the frequency of hyperamylasemia in lactic acidosis.
- Hyperamylasemia in lactic acidosis is not indicative of acidosis severity or impaired renal function.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...